by FiveSenses | Mar 20, 2026 | News Release
Montreal, QC, Canada, March 20, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a... 
by FiveSenses | Mar 9, 2026 | News Release
Montreal, QC, Canada, March 9, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private... 
by FiveSenses | Mar 2, 2026 | News Release
Montreal, QC, Canada, March 2nd, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major...
Recent Comments